Journal of Surgery Concepts & Practice >
Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment
Received date: 2023-11-13
Online published: 2024-03-04
Objective To analyze the recurrence factors of the patients with intermediate risk papillary thyroid carcinoma (PTC) after radioactive iodine treatment (RAIT). Methods A total of 254 intermediate risk PTC patients after RAIT from January 2018 to May 2020 in our hospital were enrolled into this study. Chi square test and multivariate analysis were applied to analyze the main recurrence factors after RAIT. Results Thirty four (13.4%) patients with intermediate risk PTC relapsed after RAIT. The primary tumor size, lymph node metastasis staging, and pre-ablation stimulated thyroglobulin (psTg) were associated with tumor recurrence. According to the receiver operating characteristic (ROC) curve, psTg 25.6 μg/L was the best cutoff value for predicting recurrence. Further multivariate analysis revealed that lymph node metastasis staging and psTg levels were independent factors of predicting PTC recurrence. When the patients with N1b and psTg≥25.6 μg/L, the incidence of tumor recurrence after RAIT was 58.3%. While the patients with N1a and psTg<25.6 μg/L, the incidengce of tumor recurrence was only 2.3%. Conclusions Lymph node metastasis staging and psTg level are the important indicators of PTC recurrence, and combining these two indicators can help predict tumor recurrence after RAIT.
TANG Linglin, LI Li, LAI Yi, LIU Jianjun, ZHOU Xiang . Analysis of tumor recurrence factors of the patients with intermediate risk papillary thyroid carcinoma after radioactive iodine treatment[J]. Journal of Surgery Concepts & Practice, 2023 , 28(06) : 536 -539 . DOI: 10.16139/j.1007-9610.2023.06.09
| [1] | HUANG J, NGAI C H, DENG Y, et al. Incidence and mortality of thyroid cancer in 50 countries: a joinpoint regression analysis of global trends[J]. Endocrine, 2023, 80(2):355-365. |
| [2] | HAY I D, THOMPSON G B, GRANT C S, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients[J]. World J Surg, 2002, 26(8):879-885. |
| [3] | MAZZAFERRI E L, JHIANG S M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428. |
| [4] | HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133. |
| [5] | HUNG M L, WU J X, LI N, et al. Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer[J]. JAMA Surg, 2018, 153(12):1098-1104. |
| [6] | RUEL E, THOMAS S, DINAN M, et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2015, 100(4):1529-1536. |
| [7] | TIAN T, QI Z, HUANG S, et al. Radioactive iodine therapy decreases the recurrence of intermediate-risk PTC with low thyroglobulin levels[J]. J Clin Endocrinol Metab, 2023, 108(8):2033-2041. |
| [8] | GARG A, CHOPRA S, BALLAL S, et al. Differentiated thyroid cancer in patients over 60 years of age at presentation: a retrospective study of 438 patients[J]. J Geriatr Oncol, 2015, 6(1):29-37. |
| [9] | LIU L, ZHANG X, TIAN T, et al. Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer[J]. Thyroid, 2020, 30(7):1017-1024. |
| [10] | KWON S Y, LEE S W, KONG E J, et al. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study[J]. Eur J Nucl Med Mol Imaging, 2020, 47(3):561-571. |
| [11] | SIGNORE A, LAURI C, DI PAOLO A, et al. Predictive role of serum thyroglobulin after surgery and before radioactive iodine therapy in patients with thyroid carcinoma[J]. Cancers (Basel), 2023, 15(11):2976. |
| [12] | ROSARIO P W, MOURAO G F, SIMAN T L, et al. A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low-risk papillary thyroid cancer patients: implication for radioiodine indication[J]. Clin Endocrinol(Oxf), 2015, 83(6):957-961. |
| [13] | LI S, REN C, GONG Y, et al. The role of thyroglobulin in preoperative and postoperative evaluation of patients with differentiated thyroid cancer[J]. Front Endocrinol (Lau-sanne), 2022, 13:872527. |
| [14] | PICCARDO A, ARECCO F, PUNTONI M, et al. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival[J]. Clin Nucl Med, 2013, 38(1):18-24. |
/
| 〈 |
|
〉 |